2021
DOI: 10.1016/bs.acr.2020.12.002
|View full text |Cite
|
Sign up to set email alerts
|

Immunotherapy in hepatocellular cancer

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1

Citation Types

0
0
0

Year Published

2023
2023
2024
2024

Publication Types

Select...
2

Relationship

0
2

Authors

Journals

citations
Cited by 2 publications
(1 citation statement)
references
References 107 publications
0
0
0
Order By: Relevance
“…In the past decade, there has been significant progress in the development and widespread use of anti-VEGF-VEGFR medicines, including an anti-VEGF-A neutralizing antibody and multi-kinase inhibitors. These drugs have been mostly employed in managing prominent solid tumors [110]. The therapeutic effectiveness of these medications has been thoroughly assessed, yet none provide full treatment for individuals with cancer.…”
Section: Overview Of Vegfrmentioning
confidence: 99%
“…In the past decade, there has been significant progress in the development and widespread use of anti-VEGF-VEGFR medicines, including an anti-VEGF-A neutralizing antibody and multi-kinase inhibitors. These drugs have been mostly employed in managing prominent solid tumors [110]. The therapeutic effectiveness of these medications has been thoroughly assessed, yet none provide full treatment for individuals with cancer.…”
Section: Overview Of Vegfrmentioning
confidence: 99%